Article
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Gastroenterology - 1 Oct 2015
Coenen Marieke J H, de Jong Dirk J, van Marrewijk Corine J, Derijks Luc J J, Vermeulen Sita H, Wong Dennis R, Klungel Olaf H, Verbeek Andre L M, Hooymans Piet M, Peters Wilbert H M, te Morsche Rene H M, Newman William G, Scheffer Hans, Guchelaar Henk-Jan, Franke Barbara
Abstract excerpt
BACKGROUND & AIMS: More than 20% of patients with inflammatory bowel disease (IBD) discontinue thiopurine therapy because of severe adverse drug reactions (ADRs); leukopenia is one of the most serious ADRs. Variants in the gene encoding thiopurine S-methyltransferase (TPMT) alter its enzymatic activity, resulting in higher levels of thiopurine metabolites, which can cause leukopenia. We performed a prospective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.